Episode 8 - Trump’s FDA deregulation proposal, 21st Century Cures Act, and Value-based Reimbursement Model

February 7, 2017

In this episode, I open with the latest #GOBOLDY (read: Go Boldy, not GOB OLDY) campaign by the industry trade association, PhRMA, then move onto Trump's latest request to Pharma companies to lower prices, one solution of which is his proposal on lessening FDA regulations so drugs will enter into the market faster.  I then move onto the 21st Century Cures Act to clear up any potential confusion on where this Act modifies FDA approvals process as well as a high-level overview of the Act.  Then, I move onto what the pharma companies have proposed on lowering prices, which is through value-based reimbursement models.


Facebook Comments: